ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,404Medicare Part D Prescriptions Filled, Including Refills

Rank: 15 out of 586

$459K Total Retail Price of All Prescriptions

Rank: 32 out of 586

441 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
72% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Utah
Lower avg

Schedule Two
Controlled Substances

18% of this provider’s 441 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

21% of this provider’s 441 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

1% of this provider’s 8,576 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$44 was the average price of a prescription from this provider, compared to $57 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Utah
WARFARIN SODIUM 767 627 1 13
FUROSEMIDE 419 351 2 9
HYDROCODONE-ACETAMINOPHEN 407 309 S3 3 5
SIMVASTATIN 397 309 4 1
LEVOTHYROXINE SODIUM 378 335 5 2
POTASSIUM CHLORIDE 283 237 6 14
CYMBALTA 265 221 7 29
LISINOPRIL 244 216 8 4
OMEPRAZOLE 229 214 9 3
TRAZODONE HCL 214 182 10 20
GABAPENTIN 212 166 11 11
CITALOPRAM HBR 168 129 12 12
AMLODIPINE BESYLATE 151 129 13 7
TRAMADOL HCL 142 139 14 15
MIRTAZAPINE 126 120 15 64
ALENDRONATE SODIUM 123 118 16 23
OXYCODONE HCL 118 70 S2 17 32
METFORMIN HCL 118 103 17 6
ATENOLOL 118 114 17 34
DONEPEZIL HCL 118 118 17 40
LANTUS 107 67 21 33
MORPHINE SULFATE ER 102 58 S2 22 49
QUETIAPINE FUMARATE 101 92 23 50
KLOR-CON M20 92 90 24 92
CARVEDILOL 92 88 24 30
NAMENDA 91 91 26 54
TAMSULOSIN HCL 90 85 27 27
LOSARTAN POTASSIUM 84 74 28 18
METOPROLOL TARTRATE 83 75 29 26
LEVETIRACETAM 80 64 30 119
OXYCODONE-ACETAMINOPHEN 80 40 S2 30 78
HYDROCHLOROTHIAZIDE 80 78 30 10
METOPROLOL SUCCINATE 75 75 33 19
SERTRALINE HCL 73 61 34 21
BACLOFEN 65 32 35 98
CARBIDOPA-LEVODOPA 64 62 36 89
ZOLPIDEM TARTRATE 60 47 37 8
FENTANYL 60 51 S2 37 63
OXYBUTYNIN CHLORIDE 60 51 37 83
SEROQUEL 59 55 40 118
ABILIFY 57 36 41 116
DIGOXIN 56 49 42 96
SODIUM CHLORIDE 55 44 43 229
HUMALOG 50 45 44 148
DIVALPROEX SODIUM 50 50 44 69
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 12, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.